MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.360
-0.010 (-0.73%)
At close: Apr 28, 2026, 4:00 PM EDT
1.377
+0.017 (1.26%)
After-hours: Apr 28, 2026, 6:52 PM EDT
MediciNova Employees
MediciNova had 6 employees as of December 31, 2025. The number of employees decreased by 7 or -53.85% compared to the previous year.
Employees
6
Change (1Y)
-7
Growth (1Y)
-53.85%
Revenue / Employee
$68,276
Profits / Employee
-$1,999,660
Market Cap
66.94M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| Seres Therapeutics | 66 |
| BeyondSpring | 44 |
| iBio, Inc. | 20 |
| ImageneBio | 15 |
| Actuate Therapeutics | 12 |
| Annovis Bio | 7 |
MNOV News
- 1 day ago - New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - GlobeNewsWire
- 6 weeks ago - MediciNova to Participate at the 38th Annual ROTH Conference - GlobeNewsWire
- 3 months ago - MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients - GlobeNewsWire
- 4 months ago - 2026 New Year's Greetings from the CEO - GlobeNewsWire
- 4 months ago - MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy - GlobeNewsWire
- 5 months ago - MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - GlobeNewsWire
- 5 months ago - MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor - GlobeNewsWire
- 6 months ago - MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards - GlobeNewsWire